Company intelligence / Profile preview

3-Dimensional Pharmaceuticals

Yardley, PA, United Statesen.3d-medicines.com ↗

Ownership: Private
Development stage: Commercial

Overview

3-Dimensional Pharmaceuticals developed an integrated drug discovery platform focused on structure-based design, combinatorial chemistry (DirectedDiversity), and label-free high-throughput screening (Thermofluor). They transitioned from collaboration- and technology-licensing heavy business to focus on internal pipeline assets, but clinical progress was limited, and the company was acquired by Johnson & Johnson in 2003.

Therapeutic areas: OtherImmunologyRare Diseases
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

envafolimab

NDA

Indications: Cancer

Partnerships

GlaxoSmithKline (formerly SmithKline Beecham)Johnson & Johnson

Beyond the preview

Go deeper on 3-Dimensional Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-Dimensional Pharmaceuticals.

Explore the full profile